Roy W. Ware, PhD, MBA appointed as Chief Manufacturing and Technology Officer Caryn Barnett appointed as VP, Clinical Operations Pablo Lee, MD, MBA, appointed as VP, Medical Affairs  CAMBRIDGE, United Kingdom and NEW YORK, February 16, 2026 – Artios Pharma …

DUBLIN--(BUSINESS WIRE)--Jul 31, 2025-- × Javascript is required for you to be able to read premium content. Please enable it in your browser settings. kAm%96 {6??@I 82DE2FE DJ?5C@>6 >2C<6E :D 6IA6C:6?4:?8 D:8?:7:42?E 8C@HE9 5F6 E@ E96 :?4C62D:?8 …

… Disease Foundation (CDF) via digital advertisements. Eligibility Eligible patients were English … Company. RS was employed by Jazz Pharmaceuticals, PLC until Jan 2023. DWA …

… did have that larger patient ad in the first quarter that … remarkable about the Xywav narcolepsy ads is that despite having a … now disconnect. Follow Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) Follow Jazz Pharmaceuticals Plc (NASDAQ:JAZZ …

… , and good afternoon, everyone Today, Jazz Pharmaceuticals reported its first quarter 2024 … ;A Session Follow Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) Follow Jazz Pharmaceuticals Plc (NASDAQ:JAZZ … level of difference on the ADS or the performance scale that …

New York, USA, April 17, 2024 (GLOBE NEWSWIRE) -- HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche With the improvement of …

New York, USA, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Lennox-Gastaut Syndrome Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Players to Watch Out - Zogenix, Epygenix, SK Life Science, Takeda, Jazz Pharmaceuticals, …

KINNELON, NEW JERSEY, UNITED STATES, September 14, 2023 /⁨EINPresswire.com⁩/ -- MVP (Momentum and Value for People of Color), a nonprofit 501(c)(3) organization committed to creating equity and access to opportunity for young people of color, is …

Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related to regulatory …

Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of care, with or without tislelizumab …